Furthermore, the hypothesis that IL6 is a potential target in cardiovascular disease is being currently tested in the ZEUS trial, which is being conducted to determine if ziltivekimab (a human anti-IL-6 monoclonal antibody) reduces the risk of cardiovascular events in people with cardiovascular disease, chronic kidney disease, and inflammation. Here, IL6 is linked to cardiovascular disorder.